EUVIMEDAvasta EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement

Sampriti Paul iD, Sonal Dubey iD, Prashant Tiwari iD

Chemical Biology & Drug Design · 2026-07 · 108 (1)

DOI: 10.1111/cbdd.70366 ↗

At a glance

Übersichtsarbeit in Chemical Biology & Drug Design, published online on 2026-07-23. Written by Sampriti Paul and 2 co-authors. Institution: College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru South, India. Major MEDLINE topics: Protein Serine-Threonine Kinases, Protein Kinase Inhibitors. 187 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Dual‐specificity tyrosine‐phosphorylation‐regulated kinase 1A (DYRK1A), located within the Down syndrome critical region and implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and context‐dependent cancer biology, represents a high‐value yet challenging therapeutic target. This review compiles comprehensive structure–activity relationship (SAR) insights essential for medicinal chemists designing selective DYRK1A inhibitors. We detail the molecular architecture of the ATP‐binding pocket of DYRK1A, key regulatory residues (Lys188, Phe238, Glu239, Leu241), and structure–function relationships governing inhibitor classes: ATP‐competitive agents, ATP‐non‐competitive inhibitors, and Proteolysis‐Targeting Chimeras (PROTAC) degraders with emphasis on functional group modifications and scaffold optimization strategies. Readers will gain actionable insights on binding mode predictions, potency‐selectivity trade‐offs, and prioritization of lead compounds for preclinical validation. The framework addresses pharmacokinetic property optimization and selectivity profiling across kinase families, enabling researchers to accelerate rational inhibitor design and facilitate translation of DYRK1A therapeutics into clinical trials for neurodegenerative and developmental disorders.

Subjects

MeSH terms (MEDLINE)

Protein Serine-Threonine KinasesProtein Kinase InhibitorsDyrk KinasesProtein-Tyrosine KinasesHumansStructure-Activity RelationshipBinding SitesDrug DesignAdenosine TriphosphateProteolysis Targeting ChimeraTyrosine Kinase InhibitorsAnimals

Author keywords

Alzheimer diseaseDYRK1ADown syndromeprotein kinase inhibitorstructure–activity relationship

Substances

Dyrk KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtein Kinase InhibitorsAdenosine TriphosphateProteolysis Targeting ChimeraTyrosine Kinase Inhibitors

Authors and institutions

  • College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru South, India.

ORCID profiles: Sampriti Paul, Sonal Dubey, Prashant Tiwari

Cite

APA

Paul, S., Dubey, S., & Tiwari, P. (2026). Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement. Chemical Biology & Drug Design, 108(1). https://doi.org/10.1111/cbdd.70366

Vancouver

Paul S, Dubey S, Tiwari P. Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement. Chemical Biology & Drug Design. 2026;108(1). doi:10.1111/cbdd.70366

BibTeX
@article{Paul2026,
  author = {Paul, Sampriti and Dubey, Sonal and Tiwari, Prashant},
  title = {Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {108},
  number = {1},
  doi = {10.1111/cbdd.70366}
}
Start for free →